Table 1.

Liquid biopsy assays currently in use for screening, diagnosis, and prognosis of Colorectal Cancer

Test Name (Ref)	Sample	Biomarker detected	Technology	Application
Epi proColon [9]	Plasma	SEPT9 methylation	Bisulfite converted DNA and PCR	Screening
OncoBEAM [10]	Plasma	34 RAS mutations- 16 mutations in KRAS codons 12, 13, 59, 61, 117, 146 and 18 mutations in NRAS codons 12, 13, 59, 61, 117, 146	Emulsion digital PCR with flow cytometry	Diagnostic
Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay [11]	Plasma	18 mutations in NRAS exons 2,3,4 5 mutations in BRAF codon 600 2 mutations in EGFR codon 492	PCR	Diagnostic
AdnaTest ColonCancerSelect and AdnaTest ColonCancerDetect [12]	Blood	Colon-cancer-associated gene expression of GA733-2, CEA and EGFR	PCR	Diagnostic
Guardant360 [13]	Plasma	Tumour mutation profiling (73 genes)	NGS	Diagnostic
TruSight Oncology 500 portfolio [14]	Blood	pan-cancer comprehensive genomic profiling of Single nucleotide variants (SNVs), Indels, CNVs, fusions, and IO biomarkers (TMB, MSI)	NGS	Diagnostic
CellSearch [15]	Blood	CTC with CD45-, EpCAM +  and (CK8, 18 and/or 19)	CTC immuno-isolation and detection by immune-fluorescence	Prognostic
Intplex [16]	Plasma	KRAS/NRAS/BRAF point mutations	PCR	Prognosis Treatment selection

SEPT9 Septin 9, GA733-2 Epithelial glycoprotein 40 gene, CEA Carcinoembryonic antigen, EGFR Epidermal growth factor receptor, NGS Next generation sequening, TMB Tumor mutational burden, MSI Microsatellite instability, CNV Copy Number Variations, CTC circulating tumor cells